Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
AN2 Therapeutics Inc ANTX
$5.35
▲ +0.38%
(+$0.02)
🗓️ Earnings Next Week
Open
$5.37
Prev Close
$5.33
Day Range
$5.26 – $5.66
52W Range
$1.00 – $6.91
Market Cap
$192.69M
Beta
-1.00
EPS (TTM)
$-1.10
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-03-25 |
| Shares Out. | 36,020,000 |
| Website | an2therapeutics.com/ ↗ |
| Phone | 16503319090 |
| Employees | 21 |
| Net Income | -$10.0M |
| Total Assets | $87.5M |
| Total Liabilities | $5.7M |
| Equity | $81.8M |
About AN2 Therapeutics Inc
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
AN2 Therapeutics Inc is a publicly traded company under the ticker symbol ANTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)